Rebamipide
Rebamipide is a quinolinone derivative that is used as a mucoprotective agent. It was first developed in Japan by Otsuka Pharmaceutical and is commonly used in several Asian countries, including South Korea and India.
Mechanism of Action[edit]
Rebamipide works by enhancing mucosal defense, increasing prostaglandin production, and scavenging free radicals. It also inhibits Helicobacter pylori adhesion to gastric epithelial cells.
Uses[edit]
Rebamipide is primarily used for the treatment of gastritis and peptic ulcer disease. It is also used in the treatment of dry eye disease, as it stimulates the production of mucin, a key component of the tear film.
Side Effects[edit]
Common side effects of Rebamipide include gastrointestinal disturbances, such as diarrhea and abdominal pain. Rare side effects can include skin rash, itching, and urticaria.
Contraindications[edit]
Rebamipide should not be used in patients with known hypersensitivity to the drug. It should also be used with caution in patients with a history of gastrointestinal bleeding.
Interactions[edit]
Rebamipide may interact with other drugs like antacids and proton pump inhibitors. Therefore, it is important to inform the healthcare provider about any other medications being taken.
Pharmacokinetics[edit]
Rebamipide is well absorbed from the gastrointestinal tract and is metabolized in the liver. It is excreted in the urine.
References[edit]
- Rebamipide in the treatment of gastric ulcers and gastritis: a clinical guide. Drug Design, Development and Therapy. 2018.
- Rebamipide: a novel treatment for dry eye syndrome. Clinical Ophthalmology. 2015.
| Drugs used for diseases of the alimentary tract and metabolism | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This alimentary tract and metabolism related article is a stub.
|
Template:Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
| Drugs for Dry eye syndrome | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This dry eye syndrome related article is a stub.
|
